Highlights

  • ImpediMed (ASX:IPD) is focused on expanding its SOZO medical technology platform.
  • SOZO uses bioimpedance spectroscopy to measure fluid changes associated with lymphoedema.
  • The company operates a subscription-based model supported by device placements and licence fees.
  • Revenue growth, device utilisation and Cash Management remain key areas to monitor.

ImpediMed Limited (ASX:IPD) is a medical-device company focused on bioimpedance spectroscopy technology. Its SOZO platform measures fluid levels in the body using a small electrical current and is primarily used for lymphoedema assessment following cancer treatment.

Unlike traditional hardware-only medical devices, SOZO operates through a recurring Revenue model. Healthcare providers use the devices while paying ongoing licence fees, creating a Business model linked to continued testing activity.

Recurring Revenue and Commercial Progress

ImpediMed tracks the performance of SOZO through metrics including annual recurring revenue, installed devices and patient testing volumes. For the fourth quarter of financial year 2026, the company reported quarterly revenue of approximately A$3.6 million and annual Recurring Revenue of around A$14.4 million.

During the quarter, ImpediMed reported sales of SOZO units globally and an installed base of approximately 1,236 units. Patient testing volumes also continued to increase, reflecting usage across healthcare facilities.

The company has focused on increasing adoption by supporting healthcare providers and improving integration of SOZO testing into clinical workflows.

Clinical Adoption and Market Development

Lymphoedema can develop after cancer treatment and requires ongoing monitoring. ImpediMed’s strategy is based on encouraging earlier identification and management through regular measurement.

The company has also explored additional applications of its technology, including fluid monitoring in other medical areas. Expansion into new clinical uses would depend on further development and adoption.

Financial Considerations and Future Priorities

ImpediMed continues to manage the transition from technology development to broader commercial adoption. The company reported cash of approximately A$15.3 million at 30 June 2026 and has previously raised additional Equity to support operations.

Future progress depends on increasing device utilisation, growing recurring revenue and managing operating costs. The company also needs to balance expansion activities with available financial resources.

Key Insights

ImpediMed’s SOZO platform represents a recurring-revenue healthcare technology model built around clinical monitoring rather than one-time equipment sales. The company’s next stage will depend on continued adoption by healthcare providers, increased testing activity and financial execution.